Fremman Capital is a pan-European, mid-market investment firm focused on partnering with management teams to transform local businesses into multinational sustainable leaders. Specializing in business and tech services, healthcare, consumer goods, and industrials, the company emphasizes responsible investing with ESG integration throughout its investment process. Founded with over 100 years of combined senior partner experience, Fremman Capital operates with a vision of positive societal impact.
- Healthcare
- Medical Technology
- Health Solutions
- Advanced Healthcare Solutions
- Patient Care Technology
- Healthcare Innovations
- Medical Equipment
- Sustainable Healthcare
- Ethical Management In Healthcare
Leadership
| Name | Title | ||
|---|---|---|---|
| Chris Carney | Partner |
in/chris-carney-69201024
|
|
| Managing Director |
|
|
|
| Managing Director |
|
|
|
| Founding Partner |
|
||
| CEO, Chairman & Founding Partner |
|
|
Recent Transactions involving Fremman Capital
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
Fremman Capital acquires a majority stake in Italian specialty In Vitro Diagnostics (IVD) leader DIESSE Diagnostica Senese in a bilateral transaction with private equity healthcare specialist ARCHIMED - Fremman Capital |
DIESSE Diagnostica Senese |
Fremman Capital |
In Vitro Diagnostics | |
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →